New breast cancer Drug's absorption tested in healthy volunteers
NCT ID NCT06619873
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested the drug HRS-8080 in 24 healthy adults to see how well it is absorbed and whether food changes its levels in the body. Participants took single doses under different conditions, including fasting and with low- or high-fat meals. The results will help design future trials for breast cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-8080
- What this could lead to
- If successful, this study could help determine the best way to take HRS-8080 in future trials for breast cancer.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only measures how the drug moves through the body, not whether it works against cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Frist Affiliated Hospital of USTC (Anhui Provincial Hospital)
Hefei, Anhui, 230001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?